EN DE
Watch Grand Brilliance Group Holdings Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Grand Brilliance Group Holdings Ltd (8372) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Grand Brilliance Group Holdings Ltd stock HK$0.18, price HK$0.16, upside +13.2%, quality 56 out of 100. Rating: undervalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · ISIN KYG4136R1020

GB Grand Brilliance Group Holdings Ltd logo Thin data Nov 13, 2026

Grand Brilliance Group Holdings Ltd

8372 · HK

Solid company and rising price, but only slightly cheap (12% below fair value): meets 2 of 3 rules.

Get notified free when this changes
Fair value HK$0.1800 · Undervalued 
Rising price (uptrend) 
Quality 56/100 
Expensive Growth (revenue 5y +7.5 %/yr in HKD) 
Thin margins · 8.4% net margin (TTM) 
1.9% dividend yield · Watch coverage
Mixed vs. peers (6/12) 
Revenue last quarter 9% below a year ago. 
Negative free cash flow 
Narrow moat 37/100 · thin data
Thin data 
Watch Grand Brilliance Group Holdings Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$0.1700 HK$0.0527 Fair Value HK$0.1800 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

60‑month range HK$0.0527 – HK$0.1700 · fair‑value band HK$0.1400 – HK$0.2300 · the HK$0.1590 price screens below the HK$0.1800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.

Follow Grand Brilliance Group Holdings in your weekly email

Every Wednesday you see whether Grand Brilliance Group Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Grand Brilliance Group Holdings Limited, an investment holding company, engages in supplying of medical devices in Hong Kong. The company offers medical consumables; medical instruments; and medical equipment, as well as develops healthcare products.

Show moreShow less

It also provides medical device solutions, such as market trend analysis, sourcing of medical devices, after-sale services, technical support and training services, medical devices leasing services, and quality assurance services; and autonomous mobile robots solutions, as well as holds trademarks.

The company sells its products to government department, hospitals, elderly home, universities, non-private organization, and individual end users. Grand Brilliance Group Holdings Limited was founded in 1997 and is based in Tsuen Wan, Hong Kong.

Stock analysis

Grand Brilliance Group Holdings Ltd (8372) currently trades at HK$0.1590, while our model-based Fair Value estimate is HK$0.1800, implying the stock looks roughly 12% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$0.2100 per share, and 8 of the 17 models we run sit above the HK$0.1590 price.

Bear case: the Dividend Discount group reads lowest at HK$0.0350, and 9 of the 17 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$0.1400 (bear) to HK$0.2300 (bull), the price of HK$0.1590 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Grand Brilliance Group Holdings Ltd reported revenue of HK$101M in FY2026 versus HK$72.0M in FY2022, a compound +8.8%/yr. Reported net income was HK$8.4M in FY2026, compounding +20.1%/yr from FY2022.

Key figures

Market cap HK$127M (≈ $16.2M) Micro · P/E ratio 15.9 · P/S ratio 1.26 · EPS (TTM) HK$0.0100 · Dividend yield 1.9% · Net margin 8.4% · Return on equity 7.1% · Return on assets (EBIT) 5.6% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).

What moves the price

The share trades about 6% below its 52-week high and 41% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 38% fair-value upside, at 13%, 8372 screens richer than that median.

Fair Value models

Bear HK$0.1400 Fair Value HK$0.1800 Bull HK$0.2300
Price HK$0.1590 · Upside +13.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (HK$0.0044 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income HK$0.1200 HK$0.1200 HK$0.1300 76
Owner Earnings HK$0.1400 HK$0.1800 HK$0.2300 75
EPV HK$0.1300 HK$0.1400 HK$0.1400 70
All 17 models by family
DCF Models
Owner Earnings HK$0.1400 HK$0.1800 HK$0.2300 75
Earnings-Based
Graham-Dodd HK$0.0700 HK$0.2400 HK$0.3200 64
Lynch FV HK$0.0700 HK$0.1000 HK$0.1300 61
PEG = 1.0 HK$0.0700 HK$0.1000 HK$0.1300 57
EPV HK$0.1300 HK$0.1400 HK$0.1400 70
Dividend Discount
Gordon GGM HK$0.0200 HK$0.0400 HK$0.0600 67
DDM Multi-Stage HK$0.0200 HK$0.0300 HK$0.0400 67
Multiples
P/E Multiple HK$0.1700 HK$0.2300 HK$0.2900 63
P/S Multiple HK$0.1300 HK$0.1800 HK$0.2200 58
P/B Multiple HK$0.0900 HK$0.1100 HK$0.1400 55
EV/EBIT HK$0.1700 HK$0.2100 HK$0.2400 63
EV/EBITDA HK$0.1900 HK$0.2300 HK$0.2700 64
EV/Revenue HK$0.1400 HK$0.1700 HK$0.2100 52
Asset-Based
NCAV (Graham) HK$0.0900 HK$0.1400 HK$0.1700 52
Economic Profit
Residual Income HK$0.1200 HK$0.1200 HK$0.1300 76
ROIC Compounder HK$0.1300 HK$0.1400 HK$0.1400 70
Growth Earnings
Growth-Adj P/E HK$0.1500 HK$0.2100 HK$0.2700 68

Open the full fair value analysis →

Quality Score breakdown

Overall quality 56/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 47
How much profit the company makes from its sales and capital
Quality Growth 29
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 81
Does it invest with discipline instead of growing at any price?
Low Volatility 63
How calm the share price moves, does not count
Price momentum 67
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 83
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 43/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
Start year 2021 (pandemic). Over 10 years: +6.7% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+3.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.4%
Dividend (yield on the price)1.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1.4% vs −3.8%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 7%
Pace: the 5-year rate starts in 2021 (pandemic)

Watch 8372, get fair value alerts →

Compare Grand Brilliance Group Holdings Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks

Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 56 · Above median
Fair Value upside +13.2% · Above median
Profitability
Return on equity (12 months) 7.1% · Above median
Return on assets 6.3% · Top 25%
Net margin (12 months) 8.4% · Top 25%
Operating margin (12 months) 7.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) −8.6% · Bottom 25%
Dividend yield (12 months) 1.9% · Below median

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/E (12 months) 15.9× · Pricier than median
P/B 1.09× · Pricier than median
P/S (12 months) 1.26× · Priciest 25%
EV/EBITDA 10.0× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)51 · sector 37
FUTURE (revenue growth)0 · sector 18
PAST (return on equity)28 · sector 25
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)38 · sector 54

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$16.67 HK$50.01 +200% vs 8372
Jointown Pharmaceutical Group 600998 ¥5.09 ¥11.56 +127% vs 8372
Shanghai Pharmaceuticals Holding 601607 ¥16.13 ¥35.78 +122% vs 8372
China National Medicines Corporation 600511 ¥28.38 ¥58.47 +106% vs 8372
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.35 ¥26.64 +38% vs 8372
Cencora, Inc COR $359.03 $341.58 −5% vs 8372
Henry Schein, Inc HSIC $86.22 $78.69 −9% vs 8372
McKesson Corporation MCK $1,103 $822.74 −25% vs 8372
Galenica AG GALE CHF 91.20 CHF 61.79 −32% vs 8372
Cardinal Health, Inc CAH $281.10 $163.14 −42% vs 8372

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Grand Brilliance Group Holdings Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Grand Brilliance Group Holdings Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8372

Frequently asked questions

Is Grand Brilliance Group Holdings Ltd (8372) overvalued or undervalued?
As of Nov 13, 2026, our model estimates a fair value of HK$0.1800 versus a price of HK$0.1590, about +13% upside (undervalued).
What is the fair value of 8372?
Our model-based fair value for Grand Brilliance Group Holdings Ltd is HK$0.1800 (as of Nov 13, 2026), built from audited fundamentals. The current price: HK$0.1590.
What is the quality score of 8372?
Grand Brilliance Group Holdings Ltd has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Grand Brilliance Group Holdings Ltd (8372)?
Our model-based price target is the fair value of HK$0.1800 (as of Nov 13, 2026) from 17 valuation models. Cautious scenario HK$0.1400, optimistic scenario HK$0.2300. It is a calculation from audited fundamentals, not an analyst target.
What is the Grand Brilliance Group Holdings Ltd stock forecast for 2026?
Our models put fair value at HK$0.1800, about +13% upside versus a price of HK$0.1590 (undervalued). Cautious scenario HK$0.1400, optimistic scenario HK$0.2300. The calculation is refreshed regularly with new filings.
What is the revenue of Grand Brilliance Group Holdings Ltd (8372)?
Grand Brilliance Group Holdings Ltd reported trailing-twelve-month revenue of about HK$101M (latest available figure, as of Nov 13, 2026).
Does Grand Brilliance Group Holdings Ltd pay a dividend?
Grand Brilliance Group Holdings Ltd currently shows a dividend yield of 1.89% relative to its recent price (as of Nov 13, 2026).
How much is the dividend of Grand Brilliance Group Holdings Ltd (8372) and when is the ex-dividend date?
Grand Brilliance Group Holdings Ltd pays a dividend of HK$0.003 per share a year, a dividend yield of 1.9%. The last ex-dividend date was Jul 13, 2026. A dividend has been paid every year since at least 2019. The payout ratio is 30.0% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Grand Brilliance Group Holdings Ltd (8372)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Grand Brilliance Group Holdings Ltd it is HK$0.1800 per share (as of Nov 13, 2026), against a price of HK$0.1590. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Grand Brilliance Group Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 13, 2026, 8372 trades below its calculated fair value: price HK$0.1590, fair value HK$0.1800, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8372?
No. The price is what the market pays today (HK$0.1590); the fair value is what the company's own numbers justify (HK$0.1800). For Grand Brilliance Group Holdings Ltd the two are HK$0.0210 per share apart. That gap is exactly why we show both numbers side by side.
How much is Grand Brilliance Group Holdings Ltd worth?
The market values Grand Brilliance Group Holdings Ltd at about HK$127M (market capitalisation, as of Nov 13, 2026). Per share that is HK$0.1590; our models calculate a fair value of HK$0.1800 per share.
What do the bullish and bearish scenarios say about 8372?
Our models span a range for Grand Brilliance Group Holdings Ltd: cautious scenario HK$0.1400, base HK$0.1800, optimistic HK$0.2300 per share (as of Nov 13, 2026, price HK$0.1590). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 8372?
Grand Brilliance Group Holdings Ltd trades at a price-to-earnings ratio of 15.9 (as of Nov 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.1800 is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2019 to 2026), reported earnings: 9.7. Other multiples: P/B 1.1, P/S 1.3, EV/EBITDA 10.0.
How solid is the balance sheet of Grand Brilliance Group Holdings Ltd (8372)?
Balance-sheet figures for Grand Brilliance Group Holdings Ltd (as of Nov 13, 2026): return on equity 7.1%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 8372 from its 52-week high?
Grand Brilliance Group Holdings Ltd trades at HK$0.1590, about 6% below its 52-week high of HK$0.1700 and 41% above the low of HK$0.1130 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.1800 is for.
Which stocks are comparable to Grand Brilliance Group Holdings Ltd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Grand Brilliance Group Holdings Ltd stock attractive at the current price?
The data as of Nov 13, 2026: price HK$0.1590, calculated fair value HK$0.1800 (+13%), Quality Score 56/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8372 calculated?
We run Grand Brilliance Group Holdings Ltd through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$0.1800 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Grand Brilliance Group Holdings Ltd currently trades 12% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Grand Brilliance Group Holdings Ltd (8372)?
The closing price on Nov 13, 2026 was HK$0.1590. Our model-based fair value is HK$0.1800, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Grand Brilliance Group Holdings Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Grand Brilliance Group Holdings Ltd (8372) come from?
Earnings per share at Grand Brilliance Group Holdings Ltd fell 4.2 % a year from 2016 to 2026. Broken into its drivers: revenue per share +6.9 %, EBIT margin −14.5 %, tax rate +1.1 %, residual (interest, one-offs) +3.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Grand Brilliance Group Holdings Ltd

How large is the market capitalisation of Grand Brilliance Group Holdings Ltd (8372)?
The market capitalisation of Grand Brilliance Group Holdings Ltd is HK$127M (≈ $16.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Grand Brilliance Group Holdings Ltd (8372)?
The price-to-sales ratio of Grand Brilliance Group Holdings Ltd is 1.26 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Grand Brilliance Group Holdings Ltd (8372)?
Earnings per share at Grand Brilliance Group Holdings Ltd are HK$0.0100 (price ÷ EPS = P/E 15.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Grand Brilliance Group Holdings Ltd (8372)?
The dividend yield of Grand Brilliance Group Holdings Ltd is 1.9% (payout 30.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Grand Brilliance Group Holdings Ltd (8372)?
The net margin of Grand Brilliance Group Holdings Ltd is 8.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Grand Brilliance Group Holdings Ltd (8372)?
The return on equity (ROE) of Grand Brilliance Group Holdings Ltd is 7.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Grand Brilliance Group Holdings Ltd (8372)?
On an EBIT basis the return on assets of Grand Brilliance Group Holdings Ltd is 5.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Grand Brilliance Group Holdings Ltd (8372)?
The operating margin of Grand Brilliance Group Holdings Ltd is 7.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Grand Brilliance Group Holdings Ltd (8372)?
Revenue at Grand Brilliance Group Holdings Ltd is down 8.6% versus a year earlier (3y avg +9.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Grand Brilliance Group Holdings Ltd (8372)?
Earnings per share at Grand Brilliance Group Holdings Ltd are down 27.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Grand Brilliance Group Holdings Ltd (8372) generate?
The free cash flow of Grand Brilliance Group Holdings Ltd is −HK$4.0M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Grand Brilliance Group Holdings Ltd (8372) hold?
Grand Brilliance Group Holdings Ltd holds more cash than debt, HK$51.1M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Grand Brilliance Group Holdings Ltd in the live analysis

One click puts Grand Brilliance Group Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.